Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator
Executive Summary
The Phase IIb-ready, glutamate-modulating candidate shelved by Pfizer after a portfolio review will help Biogen offset the risk posed by its Phase III Alzheimer's candidate aducanumab.
You may also be interested in...
Looking Past Aduhelm, Biogen Puts Pipeline On Display
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
TMS Stroke Deal Suggests No Big Buy From Biogen Yet
The investment community has been willing Biogen to make a big deal for some time now but a modest pact inked with Japan's TMS for its Phase II acute ischemic stroke drug suggests that management will continue to favor picking up promising compounds rather than diving into major M&A.
Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.